Yuezi Li

Yuezi Li

Auto-generated profile, based on publicly available information

Yuezi Li

Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YLYiheng Luo
Yiheng Luo
XLXundong Lin
Xundong Lin
CSChuyu Su
Chuyu Su
ZZZesen Zheng
Zesen Zheng
YLYuezi Li
Yuezi Li
XFXiaoli Feng
Xiaoli Feng
The rapid development of nanomaterials (NMs) and nanotechnology has profoundly impacted the biomedical field. Due to their unique physicochemical properties, NMs can interact with biological molecules, including proteins and DNA, to induce regulated cell death (RCD). Recent studies have demonstrated that NMs trigger RCD by promoting reactive oxygen species generation, activating signaling proteins, and disrupting intracellular ion homeostasis. Among the various forms of RCD, necroptosis, pyroptosis, ferroptosis, and cuproptosis have garnered significant research attention. Increasing evidence suggests that these emerging RCD pathways are crucial for tumor proliferation and migration, tumor microenvironment (TME) remodeling, and drug resistance mitigation. Accordingly, leveraging NM-driven RCD’s effects in designing multifunctional drug delivery systems holds great promise for cancer therapy. NMs can also serve as versatile drug carriers in synergistic treatments with targeting agents, photothermal/photodynamic therapy, and immunomodulators, thereby overcoming the limitations of conventional treatments. Collectively, this review systematically summarizes recent advancements in NM-induced RCD in cancer cells and discusses the diverse roles of RCD in tumor pathology. We highlight the innovative potential of NMs in inducing RCD through precise targeting and synergistic therapy, offering novel strategies to overcome tumor resistance and reshape the immunosuppressive TME.